Can you legally sell peptides in the UK?

Can I legally sell peptides in the UK?

UK peptide sales are not decided by the word peptide. They depend on whether your specific product, as presented and intended, meets the Human Medicines Regulations 2012 definition of a medicinal product. If it does, regulation 46 says a person may not sell, supply, or offer to sell or supply an unauthorised medicinal product. Ask the MHRA or qualified UK counsel to assess your exact offer. [1][2][4][5][6]

Under the Human Medicines Regulations 2012, a medicinal product includes any substance or combination of substances presented as having properties of preventing or treating disease in human beings, and any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or making a medical diagnosis. [1][2] The MHRA looks at the claims about what the product does, both explicit and implicit, how it is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews, and its primary intended purpose or the manner in which consumers would use it. [3][4][5]

The answer cannot be assigned to every peptide by its name. The MHRA considers claims, public presentation, intended purpose and how consumers would use a product. An answer for one formulation or sales page may not answer the question for a different one. [3][4][5]

This guide gives you a way to assemble the facts and identify the decisions that remain. It does not classify your product. In particular, the supplied evidence contains no specific SKU, formulation, buyer or proposed marketing copy that could support a verdict on an actual offer.

Key Facts

• A medicinal product includes any substance or combination of substances presented as having properties of preventing or treating disease in human beings. [1]
• The MHRA considers the claims about what a product does, explicit and implicit, and how it is presented through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews. [3][4]
• Regulation 46 says a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, and refers to exceptions in Part 10. [6][7]
• To make, assemble or import human medicines you need a manufacturer's licence from the MHRA, and to sell or supply medicines to anyone other than the patient using the medicine you need a wholesale distribution licence. [8][9]
• If you manufacture, import or distribute active substances and you are based in the UK you must register with the MHRA. [10]
• You need a GB EORI number to import goods into England, Wales or Scotland, and the commodity code on the import declaration determines the rate of duty and whether you need an import licence. [12][13]
• HMRC says you must register for VAT if total taxable turnover for the last 12 months goes over £90,000, or if you realise it is going to go over £90,000 in the next 30 days. [18][19]
• An MHRA borderline opinion is based on the information you provide, will not constitute a legal determination, and if it says a product is not a medicinal product that gives no approval to sell, supply, or advertise it in the UK. [20][21]

TL;DR

Start with the exact product and the entire buyer facing offer, then test the facts against the UK medicinal product definition. [1][2][3][4] If medicine status, an authorisation, an activity permission or an import route is unresolved, pause the offer and put the question to the MHRA or qualified UK counsel. [6][7][8][9][10][11] Company registration and a customs record answer different questions. [12][13][16][17]

The first fork: what kind of product is being offered

The first decision is whether the facts of your particular offer meet either limb of the UK medicinal product definition. One limb concerns a substance presented as having properties of preventing or treating disease in human beings. The other concerns a substance that may be used by or administered to humans with a view to restoring, correcting or modifying a physiological function through pharmacological, immunological or metabolic action, or making a medical diagnosis. [1][2]

That definition makes a catalogue category a poor substitute for a product file. Record the exact composition and form you propose to sell, the wording visible to a buyer and the purpose the seller intends. Include the proposed audience as a fact, without treating the buyer's identity as a decision by itself. The MHRA's approach considers claims, presentation and primary intended purpose or manner of use. [3][4][5] A status question therefore needs the version of the offer that a buyer would actually encounter.

Leave a blank space beside each row for the relevant file name, version date and responsible reviewer. The table is an evidence index, not a scoring system. A checked box cannot give you a product status. If a physical package says one thing while an online advert says another, preserve both versions so the question is assessed against the real presentation. Do not edit away a conflict and then describe the previous offer as if it never existed.

Consider two hypothetical profiles. In the first, a proposed catalogue entry is addressed to a laboratory and describes a defined research material without a claim about a human condition. The profile still needs its complete site context, composition and intended purpose; those missing facts remain open. In the second, the same nominal peptide appears beside language that presents it as relevant to a human condition. That presentation raises a separate question under the first limb. Neither sketch establishes a legal outcome for a real product. [1][3][4]

Record any change to formulation, package, audience or claims in the MHRA enquiry field so advice addresses the current offer. [3][4][5]

The evidence file the MHRA will examine

Gather the material that could shape the MHRA's view of this product before asking for a status opinion. The agency identifies explicit and implicit claims, presentation through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews, plus the product's primary intended purpose or consumer manner of use. [3][4][5]

Build an inventory with a separate row for every surface. Capture the package artwork and the exact text printed on it. Save the product page as it appeared on a dated review, including its title, description, images and adjacent links. Preserve advert creative, email copy and social posts that send a buyer to the page. Record customer reviews or testimonials that the store displays or amplifies. Place ingredient and specification documents in the same folder, but mark them as composition evidence rather than promotional statements. Those categories answer different questions even when they refer to the same SKU.

Name a person who can retrieve the original file behind every screenshot. A screenshot with no URL, date or version is difficult to reconcile with a later edit. For a changing webpage, retain both the image and the text version that produced it. If a distributor or agency writes the promotional copy, still put that copy in the product file. The source of a claim matters for correction, while the buyer's experience matters for understanding the presentation. [4]

Separate three voices in the record: statements your business wrote, statements a third party supplied for your use, and buyer comments that appear on a surface you control. This distinction lets a reviewer ask who can correct each item without assuming a third party's wording is outside the review. MHRA guidance expressly includes customer reviews in the presentation it considers. [4] Note whether the comment is merely retained as evidence or is actively displayed on the proposed store page.

Match each item to the exact product and audience. Where a shared category page refers to several products, identify which claim accompanies each item. Hand that indexed file to the person seeking advice. [3][4][5]

When the MHRA reviews a product concern

If a concern reaches the MHRA, prepare a response tied to the exact product and current offer. The agency reviews referrals and complaints about potential Human Medicines Regulations breaches and prioritises perceived consumer health and safety risk. This does not predict a particular case's outcome. [24]

Record the concern's date and wording, affected SKU, response owner and current offer state: draft, available, paused or revised. These are internal fields, not MHRA categories. They connect correspondence to the relevant version.

Use the evidence file section's existing snapshot index. Add the source version used for the status assessment and the precise open question. If medicine status is involved, check regulation 46 and its exception reference without inferring a breach or outcome from the complaint itself. [6][7][24]

Keep the correspondence and record who supplied each answer. Answer any clarification against the actual product and offer version. Give each affected SKU its own line. This is an internal accuracy control, not a prescribed MHRA format.

The MHRA says it aims to resolve most cases through voluntary compliance by the relevant company. [25] Its aim does not decide this case. Record any action requested, advice obtained, change owner and proof of completion. A wording edit may leave status or authorisation unresolved, so take the continuation decision to qualified UK counsel or the appropriate authority. [3][5][6]

For the wider research label audit, see Research use only: what it actually means. Link the concern record to the final product decision.

The authorisation gate for a medicinal product

If your proposed product is a medicinal product, resolve its authorisation position before making an offer to sell or supply it. Regulation 46 says a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. The provision also points to exceptions in Part 10, so the statutory analysis must check whether a real exception applies to the exact circumstances. [6][7]

The word “offer” matters for an online store. A live listing can raise the regulation's question before any parcel leaves the business. [6] Put the draft listing in a review state while medicine status or authorisation is uncertain. Ask for an identified authorisation and its relevance to this exact product, or a documented explanation of an applicable statutory exception from qualified UK counsel. Do not assume that naming an exception is the same as meeting its conditions. [6][7]

For how company registration differs from product permission, see Company formation without confusing it with product permission; activity permissions follow in the next section.

For each claimed authorisation, record its holder, exact product, scope and open conditions. A supplier's use of “approved” needs documentary support for the proposed offer. [3][6]

If medicine status or authorisation remains unresolved, the practical branch is to pause the offer and request product specific advice. The record should say “unresolved” rather than “allowed unless challenged”. This branch respects the text of regulation 46 while leaving the statutory exception and product facts for the appropriate authority or adviser. [6][7]

Manufacture, wholesale and active-substance activities

Map what your business will actually do, because MHRA guidance identifies distinct permissions for different medicine and active substance activities. It says making, assembling or importing human medicines needs a manufacturer's licence; wholesale supply of medicines to someone other than the patient using the medicine needs a wholesale distribution licence. UK based manufacture, import or distribution of active substances requires MHRA registration. [8][9][10]

Begin with verbs, not a general statement that the business “sells peptides”. Will it make or assemble a human medicine? Will it import one? Will it supply medicines on a wholesale basis to another business? Will it manufacture, import or distribute an input that falls within the active substance branch? These are different descriptions of work. For each proposed step, note the product status assumed and the person or company performing it. The MHRA source for that step can then be consulted against a specific activity. [8][9][10]

Use the matrix as an activity register. A business may have more than one row because it may perform more than one activity. Conversely, do not assign an active substance registration requirement merely because an item is called a peptide. Establish whether the relevant material meets that category before applying the branch. The cited MHRA guidance states the registration rule for UK based operators engaged in the named activities. [10] The file needs the definition and factual classification that make the rule relevant.

Avoid treating a licence category as a transferable badge. A document relevant to manufacture does not answer a wholesale question. A wholesaler's licence does not itself classify a product. The manufacturer's licence guidance and wholesale guidance use different descriptions of activity, so ask each question in its own row. [8][9] Where an overseas contractor performs a step, name that operator and record how the UK business participates rather than writing “supplier handles compliance” without evidence.

For the broader licence issue, see Do you need a license to sell peptides?; apply these UK activity distinctions to your own plan. The supplied facts do not establish any particular licence. For a closer look, read Is it legal to sell peptides in Texas?.

The UK import file for each product and route

For an overseas supply route, prepare a customs file and a separate MHRA product file before arranging a UK import. HMRC says a GB EORI number is needed to import goods into England, Wales or Scotland, and an import declaration includes a commodity code that affects duty and import licence requirements. MHRA guidance separately says an importer of a licensed human medicine needs to apply for one or more licences. [11][12][13]

Define one route at a time: origin, supplier, contractual buyer, importer, destination and the exact goods description. Write down which party is meant to make the declaration and who will retain a copy. Those fields make a shipment identifiable. They do not decide whether the item is a medicine. If the product file raises a medicinal status question, send it to the MHRA route rather than using a customs code as a proxy for the answer. [1][2][11][13]

The route worksheet is deliberately specific. A supplier may provide a generic invoice or export description, but a UK buyer still needs a reliable record of what will enter and where. In a hypothetical change, the same seller might first plan delivery into England and later plan delivery into Northern Ireland. The GB EORI statement cited here expressly concerns entry into England, Wales or Scotland. [12] Do not assume that statement settles a different destination. Recheck the relevant official import route for the changed destination and record the answer.

Likewise, a supplier's chosen commodity description cannot resolve the MHRA question. The customs code addresses the declaration and its duty or import licence consequences under HMRC guidance. [13] The medicinal product definition addresses the product's presentation and intended use. [1][2] Preserve both records, identify any difference in descriptions and ask the appropriate authority to resolve it before shipment.

When the item is treated as a licensed human medicine, MHRA's import guidance calls for one or more licences. 11] Put that question to the MHRA with the product, authorisation and operator facts rather than filling the blank from a general category. Once the route is defined, [Peptide supplier vetting checklist can support ordinary supplier diligence without answering this UK import question.

Advertising and the public store page

Review the proposed advertisement against the product's status and the territory where it will be published. Regulation 279 separately addresses advertisements of medicinal products in Great Britain and Northern Ireland. Its quoted provisions say an advert may not be published in either territory unless one of the stated conditions is in force for the product. [14][15] Obtain a jurisdiction specific reading of the full applicable provision before publishing a medicine advert.

Do this review after the product status and authorisation questions have been addressed. A claims review cannot replace those upstream decisions. If status remains open, keep the page and planned campaign in draft. If the product is within the medicine branch, ask the responsible reviewer to identify which regulation 279 provision governs the proposed advertisement. [14][15]

Use the evidence file above for the presentation record; this section tests the proposed medicine advertisement against the Great Britain or Northern Ireland condition in regulation 279. [14][15]

The territory field deserves an explicit answer. A store reachable from both Great Britain and Northern Ireland should not collapse the two quoted regulation 279 statements into one undifferentiated check. [14][15] Ask how the proposed advert reaches each territory and which provision applies.

Keep a version record after review. A revised image, customer review placement or linked landing page may alter the presentation the MHRA would see. [4] If the public page changes, compare the new version with the approved file and return material differences to the reviewer. This practice makes the approval decision traceable to the words actually published; it does not promise that any account, listing or advert will be accepted.

Company formation without confusing it with product permission

Registering a limited company establishes a legal entity, while the product and activity questions require their own records. The GOV.UK registration service registers a company with Companies House. Its certificate of incorporation confirms legal existence and shows the company number and formation date. [16][17] Those certificate fields identify the entity; they do not classify its products.

Create a formation sheet that a reviewer can match to contracts, supplier paperwork and any authority correspondence. Write the proposed company name and, when available, the registered company number and date of formation exactly as they appear on the certificate. Add the director or accountable contact who owns the peptide product file. Keep the formation document beside the business plan so a future reviewer knows which entity is intended to sell, import or hold a licence. [16][17]

The blank permission cells are intentional. A formation service answers whether the company has been registered, not whether its product presentation fits the medicinal product definition or whether an import activity needs a particular licence. [1][2][8][11][16][17] Do not put “approved” in the product field because the entity field has a certificate. Ask the named authority to answer the product or activity question with the actual facts.

Use the sheet to expose identity mismatches before they become operational assumptions. If a product page names one company, a supplier contract names another and an importer record names a third, write out which entity proposes to do each act. The cited MHRA guidance applies to activities, so the operator matters to the question posed. [8][9][10] The document you need for one operator cannot simply be attributed to another because both appear in the same commercial group.

Keep the formation date and product review date separate. A company can exist before a product has been evaluated. The certificate is useful proof for the first proposition; the MHRA and statutory sources address the second. 1][2][16][17] For broader operational setup, use [Peptide business compliance operating system once this UK decision file is built. That general process does not replace a UK product status opinion or the relevant licence evidence.

The VAT threshold and a turnover record

Monitor taxable turnover against the two HMRC taxable turnover tests using a dated ledger and forecast. HMRC says you must register if total taxable turnover for the last 12 months goes over £90,000. It also says you must register if you realise that total taxable turnover is going to go over the £90,000 threshold in the next 30 days. Ask HMRC whether another registration circumstance applies to your business. [18][19]

Keep the two calculations distinct. The first looks backwards across the last 12 months of taxable turnover. The second concerns an expectation for the next 30 days. [18][19] A monthly sales total alone cannot answer the forward question, and an optimistic forecast alone cannot replace the backward calculation. Ask HMRC or a qualified tax adviser how uncertain transactions should enter taxable turnover rather than assigning them a category from a generic product name.

This is a blank working template, not a claim about any seller's revenue. Give each revision a review date and retain the inputs used at that point. When the oldest month leaves the trailing window, calculate from the new set of months rather than carrying forward a stale total. If an invoice is corrected, update the calculation and note why it changed. These steps are a recordkeeping method for applying the two quoted taxable turnover tests to actual business data. [18][19]

Assign a regular check cadence in the business plan, with an additional review when a substantial new order changes the forward expectation. The cadence is an editorial control chosen by your business; the HMRC source cited here supplies the tests, not that schedule. [18][19] The person checking should record the date, source page and outstanding tax classification questions. A missing taxable amount should remain marked unknown until resolved by HMRC or a qualified adviser.

Do not use the VAT ledger to decide product legality. VAT registration is a tax question; the MHRA product status, authorisation and activity questions remain separate. 1][2][6][8][18][19] If the product plan changes, update the business and turnover records, but seek the applicable UK answer for each domain. [Peptide business taxes covers broader tax recordkeeping; the threshold and timing used here come from HMRC's UK registration page.

A product-specific decision before launch

Before publishing an offer, turn the product and activity records into a product specific question for the MHRA or qualified UK counsel. The MHRA borderline advice form asks for promotional claims, wording and graphics, and for information about where and how the product will be advertised. Its response is an opinion based on supplied information, not a legal determination. [20][22][23]

Assemble the enquiry pack around the actual proposed item. Include the exact composition and package version, the product page and linked material, every promotional graphic, the stated purpose and the intended audience. Name each planned advertising channel and territory. Attach the discrepancy log if the label and surrounding copy differ. The form's request for claims, graphics and advertising details makes those items directly relevant. [22][23] Put the questions in plain language: which facts make the definition uncertain, what information is missing and which activity the business proposes to perform.

Keep the result in its proper place. The MHRA says its borderline opinion is based on the information provided and will not constitute a legal determination. It also says that an opinion that a product is not medicinal does not itself approve its sale, supply or advertising in the UK. [20][21] Record exactly what was submitted and preserve the response alongside the version reviewed. If the later offer differs, identify the change and ask whether the earlier opinion still answers the current question rather than assuming it does.

Use “stop” when an unresolved issue could affect a proposed public offer and no competent answer is recorded. Use “revise” when the evidence file must be corrected before the question can be asked accurately. Use “seek advice” when the facts are assembled but classification, authorisation, exception, activity or territory needs interpretation. These are internal workflow states, not legal outcomes. The cited sources set the questions; they do not certify this unseen product. [1][2][6][7][8][9][10][11][14][15]

Ask UK counsel or the relevant authority to examine any claimed Part 10 exception against the exact product and transaction. [7] Ask the MHRA which product status and activity route applies where its guidance leaves a question open. [3][8][9][10] Ask HMRC or a tax adviser about uncertain taxable amounts under the two quoted taxable turnover tests and whether a different registration circumstance applies. [18][19] Preserve each answer with the date, underlying file version and person who will act on it. Reopen the decision if the formulation, operator, route or public claims change.

Name the person authorised inside your business to publish the reviewed page and identify remaining blockers. For general evidence maintenance, use Peptide business compliance operating system.

What to do next

1. Record the exact product, composition, intended buyer and proposed use for each SKU, keeping a separate version for each changed offer.

2. Capture labels, product pages, adverts, linked materials, testimonials and social copy in one dated review file. [4]

3. Apply both definition limbs to the specific file and mark every unresolved classification question for the MHRA. [1][2]

4. Map any medicine, wholesale, manufacture, active substance or import activity to the relevant MHRA route and the operator performing it. [8][9][10][11]

5. If importing, build the customs EORI and commodity code record for every route and check the medicine branch separately. [11][12][13]

6. Complete company formation as needed and keep a separate rolling taxable turnover record with a forward expectation check. [16][17][18][19]

7. Submit a product specific MHRA borderline enquiry or seek qualified UK advice where classification or permission remains unresolved. Keep the submitted version and response together. [20][22][23]

8. Recheck the final offer and advertisements against the product status, authority record and relevant Great Britain or Northern Ireland provision before launch. [6][14][15]

When should you book a peptide business fit call?

Book a fit call when you have a product list and need to organise unresolved classification, activity, import, advertising and VAT questions into a reviewable business plan. Bring the draft product record, proposed buyer path and the questions you intend to put to the MHRA, HMRC or qualified UK counsel. The call cannot determine legality or grant an MHRA approval.

Frequently Asked Questions

Can I legally sell peptides in the UK?

It depends on whether the specific product, as presented and intended, is a medicinal product under the Human Medicines Regulations 2012, and regulation 46 says a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. [1][2][6]

Does a research use only label make it legal to sell peptides in the UK?

No, a label alone does not settle it, because the MHRA considers claims, presentation through labelling, packaging, websites, social media and customer reviews, and the primary intended purpose of the product. 3][4][5] For the full research wording and buyer path audit, see [Research use only: what it actually means. Related guide: Grey Market Peptides: What the Label Means for Sellers.

Do I need a licence to sell peptides in the UK?

The MHRA says making, assembling or importing human medicines needs a manufacturer's licence, and selling or supplying medicines to anyone other than the patient using the medicine needs a wholesale distribution licence. 8][9] See [Do you need a license to sell peptides? for broader licensing research. For a closer look, read Is it legal to sell peptides in California?.

Can I import peptides into the UK to sell?

HMRC says you need an EORI number that starts with GB to import goods into England, Wales or Scotland, and the MHRA says that if you want to import a licensed medicine you need to apply for one or more licences. [11][12]

Do I need to register for VAT to sell peptides in the UK?

HMRC says you must register for VAT if your total taxable turnover for the last 12 months goes over £90,000, or if you realise it is going to go over the £90,000 threshold in the next 30 days. 18][19] See [Peptide business taxes for the wider tax file.

Can I advertise peptides in the UK?

Regulation 279 says a person may not publish an advertisement in Great Britain, or in Northern Ireland, for a medicinal product unless one of the listed conditions is in force for the product. [14][15]

How do I ask the MHRA whether my peptide is a medicine?

You can request borderline advice from the MHRA, which asks for the claims, wording or graphics used to promote the product and where and how it will be advertised, and which states its opinion will not constitute a legal determination. [20][21][22][23]

Sources

These primary UK legal and government sources support the cited statements; access dates refer to the recorded source review.

1. The National Archives, Human Medicines Regulations 2012, regulation 2, accessed 2026-10-05.

2. Medicines and Healthcare products Regulatory Agency, Borderline products: how to tell if your product is a medicine, accessed 2026-10-05.

3. Medicines and Healthcare products Regulatory Agency, Borderline products: explicit and implicit claims, accessed 2026-10-05.

4. Medicines and Healthcare products Regulatory Agency, Borderline products: public presentation, accessed 2026-10-05.

5. Medicines and Healthcare products Regulatory Agency, Borderline products: intended purpose, accessed 2026-10-05.

6. The National Archives, Human Medicines Regulations 2012, regulation 46, accessed 2026-10-05.

7. The National Archives, Human Medicines Regulations 2012, regulation 46, Part 10 reference, accessed 2026-10-05.

8. Medicines and Healthcare products Regulatory Agency, Apply for manufacturer or wholesaler of medicines licences, accessed 2026-10-05.

9. Medicines and Healthcare products Regulatory Agency, Apply for manufacturer or wholesaler of medicines licences, accessed 2026-10-05.

10. Medicines and Healthcare products Regulatory Agency, Register to manufacture, import or distribute active substances, accessed 2026-10-05.

11. Medicines and Healthcare products Regulatory Agency, Import a human medicine, accessed 2026-10-05.

12. HM Revenue & Customs, Import goods into the UK, accessed 2026-10-05.

13. HM Revenue & Customs, Import goods into the UK, accessed 2026-10-05.

14. The National Archives, Human Medicines Regulations 2012, regulation 279, Great Britain, accessed 2026-10-05.

15. The National Archives, Human Medicines Regulations 2012, regulation 279, Northern Ireland, accessed 2026-10-05.

16. Companies House, Register your company, accessed 2026-10-05.

17. Companies House, Register your company, certificate of incorporation, accessed 2026-10-05.

18. HM Revenue & Customs, Register for VAT, last 12 months, accessed 2026-10-05.

19. HM Revenue & Customs, Register for VAT, next 30 days, accessed 2026-10-05.

20. Medicines and Healthcare products Regulatory Agency, Request borderline advice, opinion limit, accessed 2026-10-05.

21. Medicines and Healthcare products Regulatory Agency, Request borderline advice, sale and advertising limit, accessed 2026-10-05.

22. Medicines and Healthcare products Regulatory Agency, Request borderline advice, promotional material, accessed 2026-10-05.

23. Medicines and Healthcare products Regulatory Agency, Request borderline advice, advertising channels, accessed 2026-10-05.

24. Medicines and Healthcare products Regulatory Agency, Borderline products: referrals and complaints, accessed 2026-10-05.

25. Medicines and Healthcare products Regulatory Agency, Borderline products: voluntary compliance, accessed 2026-10-05.

26. HM Revenue & Customs, Become a sole trader, accessed 2026-10-05.

Educational and legal disclaimer

This article is educational information. It is not legal, regulatory, tax, banking, medical, product, import, export, platform or payment advice. Product status and business obligations depend on the actual item, presentation, operator, route and current official requirements. Take the complete product record to the relevant UK authority and qualified advisers before making a consequential decision. The applicable decision depends on the facts of your proposed offer.